142 related articles for article (PubMed ID: 32366194)
1. Pretreatment serum soluble interleukin-2 receptor level predicts survival in patients with newly diagnosed follicular lymphoma.
Nozaki K; Sugahara H; Ueda S; Ishikawa J; Fuji S; Masaie H; Tada Y; Karasuno T; Iida M; Mitsui H; Kamae T; Saito N; Moriyama Y; Kawakami M; Kato R; Nakae Y; Kida T; Kosugi S; Nakagawa M; Uchida Y; Azenishi Y; Sakaniwa R; Kitamura T; Shibayama H
Leuk Lymphoma; 2020 Sep; 61(9):2113-2121. PubMed ID: 32366194
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment levels of serum soluble interleukin-2 receptor are useful in selecting the treatment regimen for newly diagnosed advanced-stage follicular lymphoma with low tumor burden.
Nozaki K; Sugahara H; Ueda S; Ishikawa J; Karasuno T; Iida M; Kamae T; Moriyama Y; Kawakami M; Kosugi S; Nakagawa M; Azenishi Y; Sakaniwa R; Kitamura T; Shibayama H
Int J Hematol; 2021 Aug; 114(2):217-221. PubMed ID: 33847924
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP.
Umino K; Fujiwara SI; Ikeda T; Toda Y; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Hematology; 2017 Oct; 22(9):521-526. PubMed ID: 28413914
[TBL] [Abstract][Full Text] [Related]
4. Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma.
Umino K; Fujiwara SI; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
Leuk Lymphoma; 2017 Feb; 58(2):316-323. PubMed ID: 27267694
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma.
Yoshizato T; Nannya Y; Imai Y; Ichikawa M; Kurokawa M
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):410-6. PubMed ID: 23747081
[TBL] [Abstract][Full Text] [Related]
6. High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma.
Wang L; Wang JH; Liu WJ; Wang WD; Wang H; Chen XQ; Geng QR; Lu Y; Xia ZJ
Ann Hematol; 2017 Dec; 96(12):2079-2088. PubMed ID: 28871325
[TBL] [Abstract][Full Text] [Related]
7. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
Goto N; Tsurumi H; Goto H; Shimomura YI; Kasahara S; Hara T; Yasuda I; Shimizu M; Murakami N; Yoshikawa T; Fukuno K; Takahashi T; Kito Y; Takami T; Moriwaki H
Ann Hematol; 2012 May; 91(5):705-714. PubMed ID: 22183251
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy.
Shirouchi Y; Nishimura N; Mishima Y; Ishihara Y; Asai H; Tamba M; Hirano M; Hirano K; Teramoto Y; Yoshida K; Takeuchi K; Terauchi T; Maruyama D
Sci Rep; 2023 Aug; 13(1):13713. PubMed ID: 37608029
[TBL] [Abstract][Full Text] [Related]
9. Elevated soluble IL-2 receptor levels correlate with tumor bulk of follicular lymphomas with intestinal involvement.
Iwamuro M; Shinagawa K; Okada H; Takata K; Yoshino T; Yamamoto K
Clin Biochem; 2014 Feb; 47(3):191-5. PubMed ID: 24362271
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of serum soluble interleukin-2 receptor level at diagnosis in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP.
Umino K; Fujiwara SI; Minakata D; Yamamoto C; Meguro A; Matsuyama T; Sato K; Ohmine K; Izumi T; Muroi K; Kanda Y
Leuk Lymphoma; 2019 Mar; 60(3):734-741. PubMed ID: 30188236
[TBL] [Abstract][Full Text] [Related]
11. High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective Study.
Morita-Fujita M; Katoh D; Shimomura Y; Ishikawa T
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e337-e342. PubMed ID: 31053551
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin's lymphoma: a single center study in Japan.
Kono N; Kanda Y; Yamamoto R; Chizuka A; Suguro M; Hamaki T; Arai C; Matsuyama T; Takezako N; Miwa A; Togawa A
Leuk Lymphoma; 2000 Mar; 37(1-2):151-6. PubMed ID: 10721779
[TBL] [Abstract][Full Text] [Related]
13. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
Goto H; Tsurumi H; Takemura M; Ino-Shimomura Y; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Goto N; Okuno M; Takami T; Seishima M; Moriwaki H
J Cancer Res Clin Oncol; 2005 Feb; 131(2):73-9. PubMed ID: 15503137
[TBL] [Abstract][Full Text] [Related]
14. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure.
Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Tura S; Papa G
Cancer; 1994 Sep; 74(6):1792-800. PubMed ID: 8082082
[TBL] [Abstract][Full Text] [Related]
15. Serum level of soluble interleukin-2 receptor is positively correlated with metabolic tumor volume on
Senjo H; Kanaya M; Izumiyama K; Minauchi K; Hirata K; Mori A; Saito M; Tanaka M; Iijima H; Tsukamoto E; Itoh K; Ota S; Morioka M; Hashimoto D; Teshima T;
Cancer Med; 2019 Mar; 8(3):953-962. PubMed ID: 30790452
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of soluble interlukin-2 receptor level at diagnosis on the outcome for patients with classical Hodgkin lymphoma treated with ABVD with or without radiotherapy.
Umino K; Fujiwara SI; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Ann Hematol; 2019 Sep; 98(9):2121-2129. PubMed ID: 31240469
[TBL] [Abstract][Full Text] [Related]
17. Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U).
Kitagawa J; Hara T; Tsurumi H; Goto N; Kanemura N; Yoshikawa T; Kasahara S; Yamada T; Sawada M; Takahashi T; Shimizu M; Takami T; Moriwaki H
J Cancer Res Clin Oncol; 2009 Jan; 135(1):53-9. PubMed ID: 18592269
[TBL] [Abstract][Full Text] [Related]
18. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma.
Vonderheid EC; Zhang Q; Lessin SR; Polansky M; Abrams JT; Bigler RD; Wasik MA
J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):207-20. PubMed ID: 9486676
[TBL] [Abstract][Full Text] [Related]
19. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Iijima K; Chizuka A
Eur J Haematol; 2001 Jan; 66(1):24-30. PubMed ID: 11168504
[TBL] [Abstract][Full Text] [Related]
20. [Expression of SIL-2R in Patients with Multiple Myeloma and Its Clinical Significance].
Lin P; Lin XR; Liu QL; Zhang XY; Chen GW; Xie RT; Zhang YL; DU XH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1797-1802. PubMed ID: 36476906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
